DDInter438 DDInter899
Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2).
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Conivaptan {u} (Compound) resembles {v} (Compound) Tolvaptan
Conivaptan {u} (Compound) resembles {v} (Compound) Deferasirox
Conivaptan {u} (Compound) binds {v} (Gene) AVPR1A
Conivaptan {u} (Compound) is included by {v} (Pharmacologic Class) Antidiuretic Hormone Antagonists
Conivaptan {u} (Compound) causes {v} (Side Effect) Feeling abnormal
Conivaptan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Warfarin
Conivaptan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Abiraterone
Conivaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dexamethasone
Conivaptan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Quinine
Conivaptan {u} may lead to a major life threatening interaction when taken with {v} Naloxegol
Conivaptan (Compound) resembles Tolvaptan (Compound)
Conivaptan (Compound) resembles Deferasirox (Compound)
Conivaptan (Compound) binds AVPR1A (Gene)
Conivaptan (Compound) is included by Antidiuretic Hormone Antagonists (Pharmacologic Class)
Conivaptan (Compound) causes Feeling abnormal (Side Effect)
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Warfarin
Conivaptan may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Conivaptan may cause a moderate interaction that could exacerbate diseases when taken with Quinine
Conivaptan may lead to a major life threatening interaction when taken with Naloxegol